このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

小さく生まれて小さいままだった子供たちの調査研究。治療は、1日1回のノルディトロピン®と比較して、週1回のソマパシタンです

2026年10月5日 更新者:Novo Nordisk A/S

妊娠期間に比べて小さく生まれた低身長児を対象に、週 1 回のソマパシタン治療の効果と安全性を毎日のノルディトロピン®と比較して評価する用量設定試験

The study compares 2 medicines used for the treatment of children who are born small and who stayed small: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).

Participants will either get somapacitan or Norditropin® - which treatment is decided by chance. Both participants and the study doctor will know which treatment the participants get. The study will last for 5 years. Participants will take either an injection once every week or once every day.

調査の概要

研究の種類

介入

入学 (実際)

62

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Dublin、アイルランド、D12 N512
        • CHI Crumlin Dept of Endocrinology
    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • Univ of AL at Birmingham_BRM
    • California
      • Orange、California、アメリカ、92868
        • Children's Hosp Of Orange
    • Idaho
      • Boise、Idaho、アメリカ、83712
        • St. Luke's Children's Endo
    • Minnesota
      • Minneapolis、Minnesota、アメリカ、55454
        • Univ of Minnesota M.C.H.
      • Saint Paul、Minnesota、アメリカ、55102
        • Children's Minnesota
    • New Jersey
      • Morristown、New Jersey、アメリカ、07962
        • Goryeb Children's Hospital
      • New Brunswick、New Jersey、アメリカ、08901
        • Rutgers-Rwjms
    • New York
      • Garden City、New York、アメリカ、11530
        • NYU Langone Hospital-LI
      • Mineola、New York、アメリカ、11501
        • NYU Langone Hospital-LI
      • New York、New York、アメリカ、10029
        • Icahn Sch of Med-Mt Sinai Hosp
    • Ohio
      • Cincinnati、Ohio、アメリカ、45229
        • CCHMC_Cinc
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73104
        • Univ Oklahoma Sci Ctr OK City
    • Texas
      • Fort Worth、Texas、アメリカ、76104
        • Cook Children's Hospital-Hematology-Oncology
    • Washington
      • Tacoma、Washington、アメリカ、98405
        • MultiCare Inst for Res & Innov
      • Algiers、アルジェリア、16000
        • CHU Bab El Oued Pediatrics Dept
      • Algiers、アルジェリア、16000
        • Endo and Diab Dept El Oued
      • Constantine、アルジェリア、25000
        • endocrino-diabetology department, Hospital IBN BADIS.
      • Hull、イギリス、HU3 2JZ
        • Hull Royal Infirmary
      • Liverpool、イギリス、L12 2AP
        • Alder Hey Children's Hospital
      • London、イギリス、E1 1BB
        • Royal London Hospital_London
      • Manchester、イギリス、M13 9WL
        • Royal Manchester Children's Hospital
      • Haifa、イスラエル、31096
        • Rambam MC - Department of Pediatrics A
      • Kfar Saba、イスラエル、44281
        • Meir MC - Department of Paediatrics
      • Petah Tikva、イスラエル、49202
        • Schneider MC - Endrocrinology and Diabetes
      • Florence、イタリア、50139
        • IRCCS Meyer Firenze
      • Genova、イタリア、16147
        • Ospedale Pediatrico Gaslini
      • Milan、イタリア、20122
        • Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
      • Roma、イタリア、00165
        • Ospedale Pediatrico Bambino Gesu
    • Kerala
      • Kochi、Kerala、インド、682041
        • Amrita Institute Of Medical Sciences & Research Centre
    • Maharashtra
      • Pune、Maharashtra、インド、411001
        • Jehangir Clinical Development Centre
    • New Delhi
      • New Dehli、New Delhi、インド、110029
        • All India Institute of Medical Sciences
      • Dnipro、ウクライナ、49100
        • Dnipropetrovsk Regional Children's Clinical Hospital - Endocrinology department
      • Kharkiv、ウクライナ、61093
        • Kharkiv Regional Children's Clinical Hospital - Endocrinological department
      • Kyiv、ウクライナ、04114
        • Komisarenko Institute of Endocrinology and Metabolism of NAMSU - Department of paediatric endocrine pathology
      • Tallinn、エストニア、13419
        • Tallinn Children's Hospital
      • Tartu、エストニア、50406
        • Tartu University Hospital Children's Clinic
      • Graz、オーストリア、8036
        • Med. Univ. Graz -Klinische Abteilung f. Allgemeine Pädiatrie
      • Salzburg、オーストリア、A 5020
        • LKH Salzburg- Univ. Klinik f. Kinder- und Jugendheilkunde
      • Sankt Pölten、オーストリア、3100
        • LKH St. Poelten, Kinder-und Jugendheilkunde
      • Vöcklabruck、オーストリア、4840
        • Salzkammergut-Klinikum Vöcklabruck
    • Upper Austria
      • Linz、Upper Austria、オーストリア、4020
        • Kepler Universitätsklinikum GmbH - Med Campus IV (vorm.LFKK)
    • Alberta
      • Edmonton、Alberta、カナダ、T6G 2B7
        • Stollery Children's Hospital
      • Bern、スイス、3010
        • Med. Kinder- und Poliklinik
      • Zurich、スイス、8032
        • Kinderspital Endokrinologie, Zürich
      • Esplugues Llobregat(Barcelona)、スペイン、08950
        • Hospital Sant Joan de Déu
      • Santiago de Compostela、スペイン、15706
        • Hospital Clínico de Santiago de Compostela
      • Belgrade、セルビア、11000
        • University Children's Hospital Tirsova
      • Belgrade、セルビア、11070
        • Institute for Mother and Child Health Care of Serbia
      • Kragujevac、セルビア、34000
        • University Clinical Centre Kragujevac
      • Niš、セルビア、18 000
        • Clinical Center in Nis
      • Novi Sad、セルビア、21000
        • Institute for Health Care of Children and Adolescents
      • Bangkok、タイ、10330
        • King Chulalongkorn Memorial hospital-Ped-Endocrinology
      • Bangkok、タイ、10330
        • King Chulalongkorn Memorial hospital_Ped-Endocrinology
      • Bangkok、タイ、10400
        • Phramongkutklao Hospital_Ped-Endo_Pediatrics
      • Copenhagen Ø、デンマーク、2100
        • Rigshospitalet Klinik for Vækst og Reproduktion Afsnit 5064
      • Bergen、ノルウェー、5021
        • Haukeland Universitetssykehus, Barneklinikken
      • Budapest、ハンガリー、1023
        • Észak-Közép-budai Centrum, Szent János Kórház és Szakrendelő
      • Szeged、ハンガリー、6720
        • Szegedi Tudományegyetem Gyermekgyógyászati Klinika
      • Angers、フランス、49100
        • Centre Hospitalier Universitaire D'Angers-2
      • Le Kremlin-Bicêtre、フランス、94270
        • AP-HP-HOPITAL DE BICETRE_Service d'Endocrinologie pédiatrique
      • Marseille、フランス、13005
        • Assistance Publique Hopitaux de Marseille-Hopital de La Timone-2
      • Marseille Cédex 05、フランス、13385
        • Hopital de La Timone
      • Paris、フランス、75015
        • Ap-Hp-Hopital Necker
      • Paris、フランス、75015
        • Hôpital Necker
      • Toulouse、フランス、31059
        • HOPITAL DES ENFANTS-HOPITAL PAULE DE VIGUIER - Pharmacie
      • Szczecin、ポーランド、71-252
        • SPSK nr 1 im Prof. T Sokolowskiego
      • Warsaw、ポーランド、04-730
        • Instytut ''Pomnik - Centrum Zdrowia Dziecka''
      • Riga、ラトビア、1004
        • Children's Clinical University Hospital
      • Izhevsk、ロシア、426009
        • Republic Children's Hospital of Ministry of Health of Udmurt
      • Moscow、ロシア、119435
        • Setchenov First Moscow State Medical University
      • Moscow、ロシア、125373
        • RMAPE
      • Novosibirsk、ロシア、630048
        • Children's clinical city hospital #1
      • Rostov-on-Don、ロシア、344013
        • FSBEI of Higher Education "Rostov State Medical University"
      • Saint Petersburg、ロシア、191144
        • SPSBHI City Children out-patient clinic #44
      • Samara、ロシア、443079
        • Samara Regional Children Clinical Hospital n.a. N.N. Ivanova
      • Tomsk、ロシア、634050
        • Siberian State Medical University
      • Fukuoka、日本、830-0011
        • Kurume University Hospital, Pediatrics
      • Fukuoka-shi, Fukuoka、日本、813-0017
        • Fukuoka Children's Hospital_Endocrinology and Metabolism
      • Fukuoka-shi, Fukuoka、日本、813-0017
        • Fukuoka Children's Hospital
      • Fukuyama-shi, Hiroshima、日本、721-8511
        • Fukuyama City Hospital_Department of Pediatrics
      • Kobe-shi, Hyogo、日本、650-0047
        • Hyogo Prefectual Kobe Children's Hospital Dept. Metab & endo
      • Kobe-shi, Hyogo、日本、650-0047
        • Hyogo Prefectual Kobe Children's Hospital_Metab & endo
      • Kyoto、日本、602-8566
        • Univ.HP, Kyoto Pref Univ of Medicine, Dept. of Pediatrics
      • Nara-shi, Nara、日本、630-8581
        • Nara Prefecture General Medical Center_ Nara-shi, Nara
      • Nara-shi, Nara、日本、630-8581
        • Nara Prefecture General Medical Center_Pediatric
      • Niigata-shi, Niigata、日本、951 8520
        • Niigata University Medical & Dental Hospital_Pediatrics
      • Osaka、日本、534-0021
        • Osaka City General Hospital, Pediatric Endocrinology and Me
      • Osaka、日本、594-1101
        • Osaka Women's and Children's Hospital
      • Saitama-shi, Saitama、日本、330-8777
        • Saitama Children's Medical Center, Endocrinorogy&Metabolism
      • Tokyo、日本、157 8535
        • National Center for Child Health and Dev, Endo and Metabo
      • Tokyo、日本、113-8519
        • Institute of Science Tokyo Hospital
      • Tokyo、日本、113-8519
        • Institute of Science Tokyo Hospital_Pediatrics
      • Tokyo、日本、157 8535
        • National Center for Child Health and Development_Endo and Metabo
      • Tokyo、日本、160-8582
        • Keio University Hospital_Pediatrics

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

2年~11年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Pre-pubertal children, boys:

    1. age between 2.5 and 11.0 years at screening.
    2. testes volume below 4 ml.
  • Pre-pubertal children, girls:

    1. age between 2.5 and 10.0 years at screening.
    2. Tanner stage 1 for breast development (no palpable glandular breast tissue).
  • Born small for gestational age (birth length and/or weight below -2 standard deviation scores) (according to national standards).

  • Impaired height defined as at least 2.5 standard deviations below the mean height for chronological age and gender at screening according to the standards of Centers for Disease Control and Prevention at screening.

  • Impaired height velocity defined as annualized height velocity below the 50th percentile for chronological age and gender according to the standards of Prader calculated over a time span of minimum 6 months and maximum 18 months prior to screening.

  • No prior exposure to growth hormone therapy or Insulin-like Growth Factor-I (IGF-I) treatment.

Exclusion Criteria:

  • Any known or suspected clinically significant abnormality likely to affect growth or the ability to evaluate growth with standing height measurements.
  • Children with hormonal deficiencies including suspected or confirmed growth hormone deficiency according to local practise.
  • Current inflammatory diseases requiring systemic corticosteroid treatment for longer than 2 consecutive weeks within the last 3 months prior to screening.
  • Children requiring inhaled glucocorticoid therapy at a dose of greater than 400 μg/day of inhaled budesonide or equivalents for longer than 4 consecutive weeks within the last 12 months prior to screening.
  • Concomitant administration of other treatments that may have an effect on growth, e.g but not limited to methylphenidate for treatment of attention deficit hyperactivity disorder.
  • Diagnosis of attention deficit hyperactivity disorder.
  • Prior history or presence of malignancy including intracranial tumours.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Somapacitan 0.24 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

実験的:Somapacitan 0.20 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

実験的:Somapacitan 0.16 mg/kg/week

Same treatment in main period (26 weeks) and extension period I (26 weeks). Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Somapacitan injected under the skin once a week.

アクティブコンパレータ:Norditropin® 0.035 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

アクティブコンパレータ:Norditropin® 0.067 mg/kg/day

Same treatment in main period (26 weeks) and extension period I (26 weeks). Participants will switch to Somapacitan during extension period II. Dosage of Somapacitan during extension period II will be determined based on the data from main phase.

Norditropin® injected under the skin once a day.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Height Velocity
時間枠:Baseline (week 0); week 26

Height velocity (HV) was derived from height measurements taken at baseline (week 0) and week 26 visit as: HV = (height at 26 weeks visit - height at baseline)/(time from baseline to 26 weeks visit in years). The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Ratio of Bone Age Versus Chronological Age
時間枠:Baseline (week 0); week 52

Change in ratio of bone age (years) versus chronological age (years) from baseline (week 0) to week 52 is presented. X-rays of left hand and wrist for bone age assessment according to the Greulich and Pyle atlas were taken. X-ray images were sent to a central imaging laboratory for evaluation. Chronological Age (years) was calculated as: (Date minus Date of Birth) divided by 365.25. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 52 or last trial contact, whichever came first.

Baseline (week 0); week 52
Change in Height Standard Deviation Score (HSDS)
時間枠:Baseline (week 0); week 26

Change in HSDS from baseline (week 0) to week 26 is presented. HSDS was derived using Centre for Disease Control and Prevention (CDC) standards. HSDS = [(height/population median)^skewness - 1]/(skewness * population standard deviation) where skewness, median and standard deviation is given by a reference growth table for the corresponding chronological age. The range for HSDS was -10 to +10. Negative scores indicated a height below the mean height for a child with the same age and gender, whereas positive scores indicated a height above the mean height for a child with the same age and gender. Positive value in change from baseline in HSDS indicated that HSDS was better than baseline HSDS In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Height Velocity Standard Deviation Score (HVSDS)
時間枠:Baseline (week 0); week 26

Change in HVSDS from baseline (week 0) to week 26 is presented. HVSDS was derived using Prader standards. HV SDS was calculated using the formula: HV SDS = (height velocity - mean)/standard deviation (SD), where height velocity was the height velocity variable measured, mean and SD of height velocity by gender and age for the reference population. The range for HVSDS was -10 to +10. Negative scores indicated a height velocity below the mean height velocity for a child with the same age and gender, whereas positive scores indicated a height velocity above the mean height velocity for a child with the same age and gender. Positive value in change from baseline in HVSDS indicated that HVSDS was better than baseline HVSDS. The outcome measure was evaluated based on the data from in-trial observation period. In-trial observation period: from first administration and up until week 26 or last trial contact, whichever came first.

Baseline (week 0); week 26
Change in Fasting Plasma Glucose
時間枠:Baseline (week 0); week 26

Change in fasting plasma glucose from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Steady State Beta Cell Function (HOMA-B)
時間枠:Baseline (week 0); week 26

Change in HOMA-B from baseline (week 0) to week 26 is presented. HOMA-B is a measure of the beta cell function and was calculated as follows: HOMA-B = (20 * fasting insulin (picomoles per liter [pmol/L]) * 1/6(microunit per milliliter [µU/mL]))/ FPG(mmol/L)-3.5). HOMA-beta score ranges from minus infinity to infinity (no limits). Higher score means better beta-cell function for HOMA-beta. Negative change from baseline (week 0) in HOMA-B indicated a worse outcome. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
時間枠:Baseline (week 0); week 26

Change in HOMA-IR from baseline (week 0) to week 26 is presented. Insulin resistance is a condition in which cells fail to respond to normal actions of hormone in body. HOMA-IR is calculated using a participant's fasting plasma insulin and glucose levels. HOMA-IR = fasting serum insulin (micro international units per milliliter (μU/ml)) × fasting plasma glucose (millimoles per liter (mmol/l)) / 22.5. HOMA-IR scores are classified as follows: less than 1.0: considered insulin sensitive, 0.5-1.4: considered healthy, above 1.8: considered early insulin resistance; above 2.7 is considered significant insulin resistance. HOMA-IR score ranges from 0-infinity (no upper limit). Higher the score, higher the level of insulin resistance. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Glycated Haemoglobin (HbA1c)
時間枠:Baseline (week 0); week 26

Change in HbA1c from baseline (week 0) to week 26 is presented. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor I (IGF-I) Standard Deviation Score (SDS)
時間枠:Baseline (week 0); week 26

Change in IGF-I SDS from baseline (week 0) to week 26 is presented. IGF-I SDS was provided by the central laboratory; its calculation is based on the actual value of IGF-1 minus mean reference value of IGF-1 divided by reference standard deviation of IGF-1. The range for IGF-I SDS was from -10 to +10. Negative scores indicated a IGF-I below the mean IGF-I for a child with the same age and gender, whereas positive scores indicated a IGF-I above the mean IGF-I for a child with the same age and gender. Positive value in change from baseline in IGF-I SDS indicated that IGF-I SDS was higher than baseline IGF-I SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26
Change in Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) SDS
時間枠:Baseline (week 0); week 26

Change in IGFBP-3 SDS from baseline (week 0) to week 26 is presented. The range for IGFBP-3 SDS was from -10 to +10. Negative scores indicated a IGFBP-3 below the mean IGFBP-3 for a child with the same age and gender, whereas positive scores indicated a IGFBP-3 above the mean IGFBP-3 for a child with the same age and gender. Positive value in change from baseline in IGFBP-3 SDS indicated that IGFBP-3 SDS was higher than baseline IGFBP-3 SDS. The outcome measure was evaluated based on the data from on-treatment observation period. On-treatment observation period: from first administration and up until last trial contact, week 26 or 14 days after last administration, whichever came first.

Baseline (week 0); week 26

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Reporting Anchor and Disclosure 1452、Novo Nordisk A/S

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2019年7月4日

一次修了 (実際)

2021年5月5日

研究の完了 (推定)

2026年12月23日

試験登録日

最初に提出

2019年3月15日

QC基準を満たした最初の提出物

2019年3月15日

最初の投稿 (実際)

2019年3月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月5日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NN8640-4245
  • 2018 (米国 NIH グラント/契約)
  • U1111-1207-9741 (その他の識別子:World Health Organization (WHO))
  • 2018-000232-10 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する